Jacob E. Berchuck, MD, discusses how a new epigenomic platform may influence the accessibility of PSMA-based therapies, especially for patients who may not have easy access to PSMA PET scans.

An AI-driven tool enhances stereotactic radiosurgery for small brain metastases by predicting local failure risks, optimizing radiation dosing, and personalizing MRI follow-ups.

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with ...

Ryan Motte, PharmD, CSP, reviewed the global cancer burden among men and its projected trajectory to 2050, highlighting the ...

Panelist discusses how there are many significant attributes of the bispecific antibody, which has broader applicability and can be used in widespread community centers. There are more community ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

The advent of cellular therapies, such as chimeric antigen receptor T-cell therapy, has revolutionized the field of ...

Sanjay K. Juneja, MD, discusses how artificial intelligence has evolved in 2024 to help improve early detection of cancer.

In separate, live events, Binod Dhakal, MD, MS; and Laahn H. Foster, MD, polled oncologists on therapeutic options for a ...